Recent News

• 09.17.2025 - TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.05.2025 - Cantor Global Healthcare Conference 2025
• 08.28.2025 - atai Life Sciences to Participate in September Investor Conferences
• 08.14.2025 - atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
• 07.29.2025 - Jay Olson
• 07.25.2025 - Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
• 07.23.2025 - David Bouchey
• 07.01.2025 - BPL-003 Phase 2b Data
• 07.01.2025 - atai Life Sciences Announces $50 Million Private Placement Financing

Recent Filings

• 08.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.18.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 07.02.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.02.2025 - 144 Report of proposed sale of securities
• 07.02.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material